Answers are grounded in this paper and cite their sources.
Biomarker testing in stage III/IV nonsquamous NSCLC is critical in treatment decision-making. This ambispective review included 1028 patients across three time periods to evaluate the clinical impact of evolving genomic testing platforms. Cohort 1 (C1: 2015-2017) had reflex EGFR/ALK testing. Cohort 2 (C2: 2017-2020) used limited next-generation sequencing (NGS; 15 genes), ALK, and ROS1 testing. Cohort 3 (C3: 2020-2022) used comprehensive NGS (161 genes). Larger NGS panels identified more actionable genomic alterations, but increased biopsy-to-result turnaround times and fewer patients had complete molecular results at first medical oncology consultation leading to delays in treatment initiation.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: